Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors

Recombinant preparation of human G-CSF-Leukostim (Russia)--(filgrastim; analog of Neupogen)--was administered in 31 patients (breast cancer--28; ovarian carcinoma--3) to treat or prevent chemotherapy-induced neutropenia. The latter was aborted after 2-6 injections. Due to use of Leukostim, another c...

Full description

Saved in:
Bibliographic Details
Published inVoprosy onkologij Vol. 54; no. 5; p. 639
Main Authors Korman, D B, Boronovskaia, L E, Maslova, I A, Andreeva, E V, Seregina, G V
Format Journal Article
LanguageRussian
Published Russia (Federation) 2008
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Breast Neoplasms - drug therapy
Drug Administration Schedule
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - administration & dosage
Granulocyte Colony-Stimulating Factor - therapeutic use
Humans
Injections, Intramuscular
Middle Aged
Neutropenia - chemically induced
Neutropenia - drug therapy
Ovarian Neoplasms - drug therapy
Recombinant Proteins
Russia
Treatment Outcome
Russia
Online AccessGet more information

Cover

More Information
Summary:Recombinant preparation of human G-CSF-Leukostim (Russia)--(filgrastim; analog of Neupogen)--was administered in 31 patients (breast cancer--28; ovarian carcinoma--3) to treat or prevent chemotherapy-induced neutropenia. The latter was aborted after 2-6 injections. Due to use of Leukostim, another course of chemotherapy (10 cycles) was successfully used in 5 breast cancer patients: no inhibition of hemopoiesis followed although the patients had suffered acute and persistent neutropenia from previous chemotherapy. No adverse side-effects of Leukostim administration were reported.
ISSN:0507-3758